Pharmaceutical Manufacturing of Pseudoephedrine Hydrochloride Tablets

The contract entails the manufacture of pseudoephedrine hydrochloride tablets to meet stringent FDA and USP standards, covering the full spectrum of pharmaceutical production including formulation development, tablet compression, and comprehensive quality control procedures. All manufacturing activities must adhere to regulatory compliance requirements, with particular emphasis on consistency, purity, and potency throughout the production lifecycle. Stability testing is a critical component, ensuring the product maintains its efficacy and safety over its intended shelf life under defined environmental conditions. The work is conducted as a subcontract under the Defense Logistics Agency, a component of the Department of Defense, with the NAICS code 325412 indicating classification within pharmaceutical and medicinal product manufacturing. The contract was posted in July 2026 and is linked to procurement identifier SPE2DX25D8022 with delivery order SPE2D926F7389. While specific performance locations and point of contact details are not provided, the scope confirms that all production, testing, and documentation must satisfy federal pharmaceutical standards to support federal supply needs.